---
title: "Vumedi Announces $104M Series B for AI-Powered Physician Learning Platform"
description: "Vumedi, a peer-to-peer video learning platform for physicians, has received a $104 million Series B growth investment from Oak HC/FT. The company announced the funding on November 10, 2026, in a press release."
canonical_url: https://clinicalterminal.com/article/108991277
section: funding-and-ma
byline: Victoria Shi · AI Funding Reporter
date_published: 2026-11-18T14:06:37.585Z
date_label: November 18, 2026
image: https://firebasestorage.googleapis.com/v0/b/clinical-ai-design.firebasestorage.app/o/desk-heroes%2Ffe_DpDNlBheXZcacuNJrysq%2Fhero_cf0a474ff5cb_w1920.jpg?alt=media
source: https://clinicalterminal.com
---

# Vumedi Announces $104M Series B for AI-Powered Physician Learning Platform

*[Vumedi](https://app.clinicalterminal.com/company/101526552), a peer-to-peer video learning platform for physicians, has received a $104 million Series B growth investment from [Oak HC/FT](https://app.clinicalterminal.com/company/101389327). The company announced the funding on November 10, 2026, in a press release.* [1]

The company provides an on-demand clinical resource with a library of more than 100,000 physician-led videos and nearly 5,000 podcast episodes across more than 21 specialties, according to the announcement and a social media post from Oak HC/FT. Vumedi said its artificial intelligence tools process this library to connect clinical questions with specialist experience.

**35% of Vumedi's profiled staff are individual contributors**

_Team · Seniority · Based on 40 profiled current staff; total headcount not on record · 1 manager or director for every 1.6 individual contributors_

| Level | Profiled staff | Share |
| --- | --- | --- |
| VP and above | 16 | 43% |
| Directors | 5 | 14% |
| Managers | 3 | 8% |
| Individual contributors | 13 | 35% |

_Levels classified from each person's current job title · profiled = current staff with a job here on record; a sample, not every employee · board members and advisors left out · 3 with no clear level, not in the shares · frozen 2026-11-18_

**Sales is Vumedi's largest team, 19% of profiled staff**

_Team · Departments · Based on 40 profiled current staff; total headcount not on record · 11 departments_

| Department | Profiled staff | Share |
| --- | --- | --- |
| Sales | 7 | 19% |
| Clinical | 6 | 16% |
| Data | 5 | 14% |
| Marketing | 5 | 14% |
| Customer success | 3 | 8% |
| Design | 3 | 8% |
| Engineering | 2 | 5% |
| Finance | 2 | 5% |
| Recruiting | 2 | 5% |
| Operations | 1 | 3% |
| Product | 1 | 3% |

_Departments classified from each person's current job title · profiled = current staff with a job here on record; a sample, not every employee · board members and advisors left out · 3 with no clear department, not in the shares · frozen 2026-11-18_

**Vumedi's six leaders came from 14 different companies**

_Team · Where leadership came from · 6 of 15 VP-and-up leaders have earlier employers on record · 14 distinct companies, most-shared first_

| Earlier employer | Leaders | Their titles here |
| --- | --- | --- |
| Cornerstone OnDemand | 1 | Vice President, Customer Success |
| Dialpad | 1 | Chief Financial Officer |
| Ancestry | 1 | Chief People Officer |
| Pfizer Inc | 1 | Chief Executive Officer, Board Director \| Life Science Innovation, Development, & Commercialization \| Biotechnology \| Medical Device \| Entrepreneurship \| Capital Formation |
| Everyday Health | 1 | Chief Commercial Strategy Officer |
| Box | 1 | Chief People Officer |
| Practice Fusion from Veradigm | 1 | Chief Commercial Strategy Officer |
| Nok Nok (Now OneSpan) | 1 | Chief Financial Officer |
| Hewlett Packard Enterprise | 1 | Chief People Officer |
| Saba Software, Inc | 1 | Chief Financial Officer |
| Google | 1 | Chief People Officer |
| McMahon Group | 1 | Chief Commercial Strategy Officer |
| NBCUniversal | 1 | CEO and Founder |
| Us Surgical Corporation | 1 | Chief Executive Officer, Board Director \| Life Science Innovation, Development, & Commercialization \| Biotechnology \| Medical Device \| Entrepreneurship \| Capital Formation |

_Earlier employers from LinkedIn work history, leader titles only · board seats and self-employment left out · a company counts once per leader · frozen 2026-11-18_

According to the company, the Series B capital has been used for investment in talent, research and development, product development, and outreach. Vumedi stated it will continue to invest in AI and product development to improve the searchability and accessibility of its content. [1]

“That makes access to real clinical experience more important,” said [Roman Giverts](https://app.clinicalterminal.com/person/104747700), founder and CEO of Vumedi, in the press release.

The company, founded in 2008, reported that its AI tools have been used by over 150,000 clinicians and generated more than 1 million interactions in less than a year. The announcement also stated that users of its AI tools spend 3.5 times more time on the platform compared to non-AI users, and that users have watched over 56 million minutes of educational content in the past year.

## Sources

1. [Business Wire](https://www.businesswire.com/news/home/20261110245713/en/Vumedi-Expands-AI-Powered-Physician-Learning-as-Medical-Innovation-Accelerates) — Vumedi Expands AI-Powered Physician Learning as Medical Innovation Accelerates

---
Canonical article: https://clinicalterminal.com/article/108991277  
Entity profiles referenced above resolve to https://app.clinicalterminal.com.
